Depression could be associated with a larger brain network

Publicly released:
International
Image by Gerd Altmann from Pixabay
Image by Gerd Altmann from Pixabay

People with depression could be more likely to have a brain network that is two times larger than those without depression, according to international researchers. The team analysed the brain networks of 141 people with a diagnosis of major depression and 37 healthy controls, as well as analysed existing large datasets. They found a group of brain regions, collectively known as the frontostriatal salience network, had expanded nearly two-fold in the brains of most people studied with depression, compared to people without depression. The expansion was found to be stable over time, unaffected by mood and could be detected in kids before depression symptoms start in adolescence. While more studies are needed, the team says this network could potentially become a marker for depression risk.

Media release

From: Springer Nature

2.  Neuroscience: Depression may be associated with an expanded brain network

A brain network observed to be nearly two times larger in most sampled individuals with depression than in healthy counterparts is identified in a study published in Nature. The findings highlight new potential targets for future therapeutic interventions.

Despite decades of neuroimaging studies, only modest differences in brain structure and connectivity have been identified in people with depression, thereby limiting current understanding of the mechanisms or risk factors for the onset of the illness. In addition, a lack of long-term studies, accounting for the episodic nature of depression, have limited the investigation of the mechanisms underlying mood state transitions in depression.

To investigate the neurobiological underpinnings of depression, Charles Lynch, Conor Liston and colleagues used a technique called precision functional mapping in a primary analysis of 141 individuals (average age 41 years) with a diagnosis of major depression and 37 healthy controls. Analyses were replicated in multiple existing large datasets. The authors found that a group of brain regions, collectively known as the frontostriatal salience network, had expanded nearly two-fold in the brains of most individuals studied with depression, compared to controls. This expansion was found to be stable over time, unaffected by changes in mood state, and could be detected in children before the onset of depressive symptoms in adolescence. The latter suggests that expansion of the frontostriatal salience network may potentially serve as a biomarker for depression risk, although the authors note that further studies are needed to confirm this association. Longer-term analyses of individuals scanned up to 62 times over a period of 1.5 years identified connectivity changes associated with depression symptoms.

In summary, the findings reveal differences in network size, shape and spatial location that are associated with depression.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Springer Nature, Web page The URL will go live after the embargo lifts.
Journal/
conference:
Nature
Research:Paper
Organisation/s: Weill Cornell Medicine, USA
Funder: This work was supported by grants to C.L. from the National Institute of Mental Health, the National Institute on Drug Addiction, the Hope for Depression Research Foundation and the Foundation for OCD Research. C.J.L. was supported by an NIMH F32 National Research Service Award (F32MH120989). N.S. was supported by K23 MH123864. Work on ‘Personalized therapeutic neuromodulation for anhedonic depression’ is supported by Wellcome Leap as part of the Multi-Channel Psych Program. M.L. was supported by Deutsche Forschungsgemeinschaft (DFG grant CRC 1193, subproject B01). Competing interests C.L. and C.J.L. are listed as inventors for Cornell University patent applications on neuroimaging biomarkers for depression which are pending or in preparation. C.L. has served as a scientific advisor or consultant to Compass Pathways PLC, Delix Therapeutics and Brainify.AI. The remaining authors declare no competing interests.
Media Contact/s
Contact details are only visible to registered journalists.